Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559780 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL21039571 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21124355 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL31250298 | 0.77 | POLB (0.54) | SMN1; SMN2ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL12774215 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1KDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL24912208 | 0.76 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPT | |
| SCHEMBL2102997 | 0.73 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL7008499 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL81624 | 0.73 | L3MBTL1 (0.39) | ALDH1A1TDP1KDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL22618146 | 0.72 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020247298-A2 | 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821115-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | SMN1; SMN2 1842/4885ALDH1A1 1575/4885HPGD 2609/4885 |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | PMP22, MYT1, IDE | SMN1; SMN2 119/4885ALDH1A1 568/4885HPGD 1990/4885 |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | SMN1; SMN2 32/4885ALDH1A1 1464/4885HPGD 2649/4885 |
| US-20200171043-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | SMN1; SMN2 1842/4885ALDH1A1 1575/4885HPGD 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.